'Mapping' Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare Diseases

被引:16
|
作者
Meregaglia, Michela [1 ]
Whittal, Amanda [1 ]
Nicod, Elena [1 ]
Drummond, Michael [2 ]
机构
[1] Bocconi Univ, Res Ctr Hlth & Social Care Management CERGAS, Milan, Italy
[2] Univ York, Ctr Hlth Econ, York, N Yorkshire, England
关键词
QUALITY-OF-LIFE; PATIENT-REPORTED OUTCOMES; EORTC QLQ-C30; FUNCTIONAL ASSESSMENT; CANCER-THERAPY; EUROPEAN ORGANIZATION; CUSHINGQOL SCORES; DECISION-MAKING; CLINICAL-TRIALS; QOL-AGHDA;
D O I
10.1007/s40273-020-00897-4
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background The use of patient-reported outcome measures (PROMs) to monitor the effects of disease and treatment on patient symptomatology and daily life is increasing in rare diseases (RDs) (i.e. those affecting less than one in 2000 people); however, these instruments seldom yield health state utility values (HSUVs) for cost-utility analyses. In such a context, 'mapping' allows HSUVs to be obtained by establishing a statistical relationship between a 'source' (e.g. a disease-specific PROM) and a 'target' preference-based measure [e.g. the EuroQol-5 Dimension (EQ-5D) tool]. Objective This study aimed to systematically review all published studies using 'mapping' to derive HSUVs from non-preference-based measures in RDs, and identify any critical issues related to the main features of RDs, which are characterised by small, heterogeneous, and geographically dispersed patient populations. Methods The following databases were searched during the first half of 2019 without time, study design, or language restrictions: MEDLINE (via PubMed), the School of Health and Related Research Health Utility Database (ScHARRHUD), and the Health Economics Research Centre (HERC) database of mapping studies (version 7.0). The keywords combined terms related to 'mapping' with Orphanet's list of RD indications (e.g. 'acromegaly') in addition to 'rare' and 'orphan'. 'Very rare' diseases (i.e. those with fewer than 1000 cases or families documented in the medical literature) were excluded from the searches. A predefined, pilot-tested extraction template (in Excel (R)) was used to collect structured information from the studies. Results Two groups of studies were identified in the review. The first group (n = 19) developed novel mapping algorithms in 13 different RDs. As a target measure, the majority used EQ-5D, and the others used the Short-Form Six-Dimension (SF-6D) and 15D; most studies adopted ordinary least squares (OLS) regression. The second group of studies (n = 9) applied previously published algorithms in non-RDs to comparable RDs, mainly in the field of cancer. The critical issues relating to 'mapping' in RDs included the availability of very few studies, the relatively high number of cancer studies, and the absence of research in paediatric RDs. Moreover, the reviewed studies recruited small samples, showed a limited overlap between RD-specific and generic PROMs, and highlighted the presence of cultural and linguistic factors influencing results in multi-country studies. Lastly, the application of existing algorithms developed in non-RDs tended to produce inaccuracies at the bottom of the EQ-5D scale, due to the greater severity of RDs. Conclusions More research is encouraged to develop algorithms for a broader spectrum of RDs (including those affecting young children), improve mapping study quality, test the generalisability of algorithms developed in non-RDs (e.g. HIV) to rare variants or evolutions of the same condition (e.g. AIDS wasting syndrome), and verify the robustness of results when mapped HSUVs are used in cost-utility models.
引用
收藏
页码:557 / 574
页数:18
相关论文
共 50 条
  • [1] ‘Mapping’ Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare Diseases
    Michela Meregaglia
    Amanda Whittal
    Elena Nicod
    Michael Drummond
    [J]. PharmacoEconomics, 2020, 38 : 557 - 574
  • [2] Mapping to Estimate Health-State Utility from Non-Preference-Based Outcome Measures: An ISPOR Good Practices for Outcomes Research Task Force Report
    Wailoo, Allan J.
    Hernandez-Alava, Monica
    Manca, Andrea
    Mejia, Aurelio
    Ray, Joshua
    Crawford, Bruce
    Botteman, Marc
    Busschbach, Jan
    [J]. VALUE IN HEALTH, 2017, 20 (01) : 18 - 27
  • [3] SYSTEMATIC LITERATURE REVIEW OF HEALTH STATE UTILITY VALUES IN PATIENTS WITH MIGRAINE
    Desai, P. R.
    Ahuja, A.
    Pietri, G.
    Sapra, S.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A760 - A760
  • [4] Health state utility values by cancer stage: a systematic literature review
    Mir-Masoud Pourrahmat
    Ashley Kim
    Anuraag R. Kansal
    Marg Hux
    Divya Pushkarna
    Mir Sohail Fazeli
    Karen C. Chung
    [J]. The European Journal of Health Economics, 2021, 22 : 1275 - 1288
  • [5] Health state utility values by cancer stage: a systematic literature review
    Pourrahmat, Mir-Masoud
    Kim, Ashley
    Kansal, Anuraag R.
    Hux, Marg
    Pushkarna, Divya
    Fazeli, Mir Sohail
    Chung, Karen C.
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2021, 22 (08): : 1275 - 1288
  • [6] Systematic literature review of health state utility values in patients with migraine
    Desai, P.
    Ahuja, A.
    Pietri, G.
    Sapra, S.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 180 - 180
  • [7] A Systematic Review of Health State Utility Values in the Plastic Surgery Literature
    Christopher, Adrienne N.
    Morris, Martin P.
    Patel, Viren
    Klifto, Kevin
    Fischer, John P.
    [J]. PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN, 2021, 9 (11)
  • [8] UTILITY STUDIES IN RARE DISEASES: A SYSTEMATIC LITERATURE REVIEW
    Ruban-Fell, B.
    van Pelt, R.
    Wright, S.
    Abdullah, A.
    Upadhyaya, S.
    Griffiths, A.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S445 - S445
  • [9] Systematic Searching and Selection of Health State Utility Values from the Literature
    Papaioannou, Diana
    Brazier, John
    Paisley, Suzy
    [J]. VALUE IN HEALTH, 2013, 16 (04) : 686 - 695
  • [10] SYSTEMATIC LITERATURE REVIEW OF HEALTH STATE UTILITY VALUES (HSUVS) IN MULTIPLE SCLEROSIS
    Badgujar, L.
    Khurana, V
    Malepati, A.
    Ranjan, P.
    Adlard, N. E.
    [J]. VALUE IN HEALTH, 2019, 22 : S753 - S753